<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39438540</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Changes in breast cancer incidence and surgical treatment in Baden-Württemberg (Germany) during the COVID-19 pandemic.</ArticleTitle><Pagination><StartPage>24912</StartPage><MedlinePgn>24912</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24912</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75084-y</ELocationID><Abstract><AbstractText>The COVID-19 pandemic affected the diagnostics and treatment of breast cancer. Numerous studies reported an early decline in breast cancer (BC) incidence during the COVID-19 pandemic. Less evidence is available on changes in medical care. Reports from individual patients have provided anecdotal evidence for a shift from breast-conserving surgery to mastectomy to reduce the number of visits to radiation units during the pandemic. This study aimed to explore changes in BC incidence and surgical treatment in the south of Germany. Using data from the Baden-Württemberg Cancer Registry, the age-standardized incidence of BC (ICD-10 C50 and D05) (women) in 2018-2021 was investigated overall and by age and stage using standardized incidence ratios. Among pre-operative stage I/IIA BC patients, differences in the time to surgery and type of surgery were investigated using negative binomial and logistic regression models. The incidence of invasive BC decreased significantly from 170.9 per 100,000 women in 2018/2019 to 159.7 in 2020 and increased to 169.2 in 2021. This decrease resulted from a lower incidence around April 2020 and was also observed for non-invasive BC. In 2021, incidence of invasive BC was still decreased by 8% in women aged 80 + years. Surgical treatment was analyzed in 22,708 BC patients with a pre-operative stage ≤ IIA. The median time to surgery was 33 days in 2018/2019, 32 days in 2020 and 36 days in 2021. The proportion of mastectomies increased from 16.1% in 2018/2019 to 17.1% in 2020 and 17.3% in 2021 (adjusted odds ratio and 95% confidence interval (2021 vs. 2018/2019): 1.13 (1.03-1.24)). The adjusted increase was strongest for patients aged 50-59 years (1.34 (1.09-1.64)) and those with high-grade tumors (1.27 (1.07-1.51)). While the early return to pre-pandemic age-standardized BC incidence rates is promising, missed cases have not been caught up until 2021. Furthermore, the decreased incidence in elderly women in 2021 warrants further attention. In early-stage BC, a slightly greater rate of mastectomies was observed, although such a change was not recommended. This result underlines the importance of good communication of adapted treatment guidelines in such exceptional circumstances.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Lina</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Epidemiological Cancer Registry Baden-Württemberg, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany. l.jansen@dkfz-heidelberg.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Silke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Epidemiological Cancer Registry Baden-Württemberg, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergbold</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Epidemiological Cancer Registry Baden-Württemberg, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arndt</LastName><ForeName>Volker</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Epidemiological Cancer Registry Baden-Württemberg, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120, Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="Y">Mastectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Germany</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Mastectomy</Keyword><Keyword MajorTopicYN="N">Surgery</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438540</ArticleId><ArticleId IdType="pmc">PMC11496798</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75084-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75084-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 (Epub ahead of print.).</Citation><ArticleIdList><ArticleId IdType="pubmed">38572751</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer in Germany 2019/2020. 14th edition. Robert Koch Institute (ed.) and the Association of Population-based Cancer Registries in Germany (ed.). Berlin, Germany, 2024.</Citation></Reference><Reference><Citation>Katalinic, A., Eisemann, N., Kraywinkel, K., Noftz, M. R. &amp; Hübner, J. Breast cancer incidence and mortality before and after implementation of the German mammography screening program. Int. J. Cancer.147(3), 709–718 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31675126</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, 2021, AWMF Registernummer: 032–045OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ (Accessed: 3 April 2024).</Citation></Reference><Reference><Citation>Darby, S. et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet378(9804), 1707–1716 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3254252</ArticleId><ArticleId IdType="pubmed">22019144</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahresbericht Evaluation 2020. Deutsches Mammographie-Screening-Programm. Kooperationsgemeinschaft Mammographie, Berlin, Germany, Dezember 2022.</Citation></Reference><Reference><Citation>de Azambuja, E. et al. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer. ESMO Open5(Suppl 3), e000793 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7295852</ArticleId><ArticleId IdType="pubmed">32439716</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics Office. GENESIS-Online, Table 12411–0013: Population: Federal States, key date, sex, age years. [https://www-genesis.destatis.de/genesis/online] (accessed: 11 January 2023).</Citation></Reference><Reference><Citation>Brierley, J. D., Gospodarowicz, M. K. &amp; Wittekind, C. TNM Classification of Malignant Tumours 8th edn. (Wiley-VCH, 2016).</Citation></Reference><Reference><Citation>Stegmaier, C. et al. Das Manual der Krebsregistrierung (W. Zuckschwerdt Verlag, 2018).</Citation></Reference><Reference><Citation>Tolksdorf, K., Loenenbach, A. &amp; Buda, S. Dritte Aktualisierung der “Retrospektiven Phaseneinteilung der COVID-19-Pandemie in Deutschland”. Epidemiologisches Bullet.38, 3–6 (2022).</Citation></Reference><Reference><Citation>Muschol, J., Strauss, C. &amp; Gissel, C. COVID-19 related decline in cancer screenings most pronounced for elderly patients and women in Germany: A claims data analysis. J. Cancer Res. Clin. Oncol.149(8), 5345–5367 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9702775</ArticleId><ArticleId IdType="pubmed">36436091</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahresbericht Evaluation 2021. Deutsches Mammographie-Screening-Programm. Kooperationsgemeinschaft Mammographie, Berlin, Germany, November 2023.</Citation></Reference><Reference><Citation>Onkologische Versorgung während der COVID-19-Pandemie: Warnung vor einer Bugwelle an zu spät diagnostizierten Krebsfällen [https://www.krebsgesellschaft.de/onkologische-versorgung-waehrend-der-covid-19-pandemie-warnung-vor-einer-bugwelle-an-zu-spaet-diagnostizierten-krebsfaellen.html] (accessed: 4 April 2024) [press release].</Citation></Reference><Reference><Citation>Li, T. et al. A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis. Breast67, 78–88 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9813855</ArticleId><ArticleId IdType="pubmed">36646004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibfelt, E. H. et al. Diagnosis and treatment of breast cancer in Denmark during the COVID-19 pandemic: a nationwide population-based study. Acta Oncol.62(12), 1749–1756 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37750293</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido-Cantero, G. et al. Madrid cancer registry (RTMAD) investigators. Impact of the COVID-19 pandemic on cancer diagnosis in Madrid (Spain) based on the RTMAD tumor registry (2019–2021). Cancers15(6), 1753 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10046347</ArticleId><ArticleId IdType="pubmed">36980640</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock, H. M. et al. Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: A year-long, population-level analysis. ESMO Open6(4), 100197 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8411068</ArticleId><ArticleId IdType="pubmed">34474811</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene, G. et al. Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system. Br. J. Cancer.127(3), 558–568 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9060409</ArticleId><ArticleId IdType="pubmed">35501391</ArticleId></ArticleIdList></Reference><Reference><Citation>Eijkelboom, A. H. et al. Impact of the COVID-19 pandemic on breast cancer incidence and tumor stage in the Netherlands and Norway: A population-based study. Cancer Epidemiol.87, 102481 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37897970</ArticleId></ArticleIdList></Reference><Reference><Citation>Eijkelboom, A. H. et al. Changes in breast cancer treatment during the COVID-19 pandemic: A Dutch population-based study. Breast Cancer Res. Treat.197(1), 161–175 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9638417</ArticleId><ArticleId IdType="pubmed">36334188</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung, S. H. et al. Impact of the COVID-19 pandemic on delays to breast cancer surgery: Ripples or waves?. Ann. Surg. Oncol.30(10), 6093–6103 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37526751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gremke, N. et al. Therapy delay due to COVID-19 pandemic among European women with breast cancer: Prevalence and associated factors. J. Cancer Res. Clin. Oncol.149(13), 11749–11757 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10465653</ArticleId><ArticleId IdType="pubmed">37405476</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia, D. et al. What is elective oncologic surgery in the time of cOVID-19? A literature review of the impact of surgical delays on outcomes in patients with cancer. Clin. Oncol. Res.3(6), 1–11 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8208646</ArticleId><ArticleId IdType="pubmed">34142081</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson, B. A., Waddimba, A. C., Ogola, G. O., Fleshman, J. W. Jr. &amp; Preskitt, J. T. A systematic review and meta-analysis of surgery delays and survival in breast, lung and colon cancers: Implication for surgical triage during the COVID-19 pandemic. Am. J. Surg.222(2), 311–318 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834494</ArticleId><ArticleId IdType="pubmed">33317814</ArticleId></ArticleIdList></Reference><Reference><Citation>Forner, D. et al. Psychosocial distress in adult patients awaiting cancer surgery during the COVID-19 pandemic. Curr Oncol.28(3), 1867–1878 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8161781</ArticleId><ArticleId IdType="pubmed">34068441</ArticleId></ArticleIdList></Reference><Reference><Citation>Roskam, J. S. et al. The effects of the COVID-19 pandemic on mastectomy outcomes for breast cancer. Clin. Breast Cancer23(4), 431–435. 10.1016/j.clbc.2023.02.010 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9951028</ArticleId><ArticleId IdType="pubmed">36990842</ArticleId></ArticleIdList></Reference><Reference><Citation>Battistello, C. Z., da Silva, N. W. &amp; Remor, E. What is the relationship between body image and the quality of life of women who underwent surgery for breast cancer? A scoping review. Psychooncology33(3), e6329 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38502048</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>